(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 8.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 256.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.88%.
Veracyte's revenue in 2025 is $463,393,000.On average, 4 Wall Street analysts forecast VCYT's revenue for 2025 to be $39,236,168,313, with the lowest VCYT revenue forecast at $39,157,305,500, and the highest VCYT revenue forecast at $39,377,369,557. On average, 4 Wall Street analysts forecast VCYT's revenue for 2026 to be $42,687,336,591, with the lowest VCYT revenue forecast at $42,340,011,291, and the highest VCYT revenue forecast at $43,557,020,346.
In 2027, VCYT is forecast to generate $46,908,102,551 in revenue, with the lowest revenue forecast at $45,789,769,906 and the highest revenue forecast at $48,428,972,296.